The $500 Million Non-CF Factor Vertex Investors Can’t Ignore on Nov. 2
Vertex reports Q3 earnings on Nov. 2 with cystic fibrosis revenue still dominant, but a $500 million target for two newer therapies will tell investors whether the company can actually launch at scale beyond its core franchise before a major…
Vertex Pharmaceuticals (NASDAQ:VRTX | VRTX Price Prediction) reports third-quarter results on Nov. 2. Cystic fibrosis still pays the bills, but I’ll be watching whether CASGEVY and JOURNAVX stay on pace for management’s $500 million non-CF revenue target.
Diversification Picks Up Speed After a Raised Outlook
Second-quarter revenue rose 12.4% to $3.33 billion, exceeding the $3.22 billion consensus. Adjusted EPS of $4.73 missed the $4.75 estimate. CASGEVY revenue rose 151% to $76.4 million, and JOURNAVX revenue more than quadrupled to $49.6 million.
Spending climbed too. Non-GAAP SG&A rose 45% on pain and renal investments, and management expects operating expenses at the high end of its $5.65 billion to $5.75 billion range.
Vertex still raised full-year revenue guidance to $13.10 billion to $13.20 billion. It then closed the Crinetics acquisition on September 1, 2026, adding rare endocrine diseases as a fifth pillar. Shares are up 16.42% year to date and 5.61% over the past week.
Wall Street Models a Crinetics Hit
| Metric | Consensus | Prior Year | YoY Change |
|---|---|---|---|
| Q3 EPS | -$1.1999 | $4.80 | N/M |
| Q3 Revenue | $3.42 billion | $3.08 billion | 11.2% |
| FY 2026 EPS | $16.1914 | $18.40 | -12.0% |
| FY 2026 Revenue | $13.26 billion | $12.00 billion | 10.5% |
Ninety days ago, the Q3 EPS consensus stood at $4.9090. Vertex counts acquired in-process R&D in its non-GAAP expenses, so analysts appear to be modeling a Crinetics charge. Estimates now range from -$29.51 to $5.06, which makes revenue the cleaner read this quarter.
CASGEVY Infusions and JOURNAVX Scripts Will Set the Tone
CASGEVY and JOURNAVX delivered about $200 million combined through June, leaving roughly $300 million to go. On the August call, Charles Wagner said Vertex is “very confident in getting to that $500 million plus.”
For CASGEVY, I’ll be watching how many patients move through to infusion. Vertex logged more than 100 patient starts in Q2, its third straight quarter above that level. The pediatric approval adds about 5,500 eligible patients. Management warned that quarterly revenue will stay variable because it depends on infusion timing.
JOURNAVX reached about 535,000 prescriptions in Q2, ahead of forecast. Patients also used the support program more than expected, and management expects gross-to-net to normalize in the first half of 2027. Q2 got a lift from channel build after a Q1 decline, so you should watch for inventory swings.
Results from the core business still matter. TRIKAFTA/KAFTRIO revenue is falling as ALYFTREK adoption speeds up, and BofA forecasts Trikafta sales of $2.42 billion, 5% below consensus. I also want to see updated guidance that includes Crinetics, plus more detail on gross margin. Management guided it to just under 86% as CASGEVY becomes a bigger part of the mix.
A Renal Launch Is Weeks Away
This report lands weeks before the Nov. 30 FDA action date for povetacicept in IgA kidney disease, and Vertex has finished hiring its renal field force. After last year’s Q3 report, shares fell about 10% on concerns about the pace of diversification. Clear progress toward $500 million in non-CF revenue would show Vertex can launch at scale outside CF. That track record would make the povetacicept rollout far more credible heading into 2027.
Contact [email protected] for any questions or corrections.
After two decades of patrolling the dark corners of suburbia as a police officer, Rich Duprey hung up his badge and gun to begin writing full time about stocks and investing. For the past 20 years, he’s been cruising the markets looking for companies to lock up as long-term holdings in a portfolio while writing extensively on the broad sectors of consumer goods, technology, and industrials. Because his experience isn’t from the typical financial analyst track, Rich is able to break down complex topics into understandable and useful action points for the average investor. His writings have appeared on The Motley Fool, InvestorPlace, Yahoo! Finance, Money Morning, and, of course, 24/7 Wall St. He has been featured in both U.S. and international publications, including MarketWatch, Financial Times, Forbes, Fast Company, and USA Today.
